A Phase 3, Multi-Center, Randomized, Open-Label Study of Carbavance (Meropenem/Vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae

Trial Profile

A Phase 3, Multi-Center, Randomized, Open-Label Study of Carbavance (Meropenem/Vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Meropenem/vaborbactam (Primary)
  • Indications Enterobacteriaceae infections
  • Focus Registrational; Therapeutic Use
  • Acronyms TANGO 2
  • Sponsors Rempex Pharmaceuticals; The Medicines Company
  • Most Recent Events

    • 16 Apr 2018 According to a Melinta Therapeutics media release, detailed results will be presented at the upcoming European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting.
    • 13 Mar 2018 According to Rempex Pharmaceuticals media release, additional data and potential publications are expected in 2018.
    • 08 Oct 2017 Results presented at the IDWeek 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top